Markets:

Overview

News

Currencies

International

Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

328.31 +20.26 (+6.58%)

Streaming Delayed Price Updated: 1:14 PM EDT, Mar 25, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies ↗

November 07, 2025

The company remains confident in its other gene-editing product, which would treat a swelling disorder.

Via Investor's Business Daily

Topics Death

What Does the Market Think About Alnylam Pharmaceuticals Inc? ↗

November 06, 2025

Via Benzinga

Alnylam to Webcast Presentations at Upcoming November Investor Conferences

November 04, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗

November 02, 2025

Via Benzinga

Earnings Scheduled For October 30, 2025 ↗

October 30, 2025

Via Benzinga

Why Is Alnylam Pharmaceuticals Stock Trading Lower Thursday? ↗

October 30, 2025

Alnylam stock fell after a strong Q3 with $2.90 EPS and $1.25 billion revenue, a subpoena disclosure, and raised 2025 sales guidance to $3.6 billion–$3.8 billion.

Via Benzinga

Topics Law Enforcement

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) Stock Dips Despite Blowout Q3 2025 Earnings ↗

October 30, 2025

Alnylam's Q3 2025 earnings crushed estimates with a $2.90 EPS and 149% revenue growth, driven by AMVUTTRA, despite a pre-market stock dip.

Via Chartmill

Alnylam Stock Has Already Doubled In 2025. Why It Could Rocket Again On Earnings. ↗

October 30, 2025

The company easily beat third-quarter expectations and issued guidance that widely topped forecasts.

Via Investor's Business Daily

Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress

October 30, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday? ↗

October 30, 2025

Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome...

Via Benzinga

Topics Economy

Uncovering Potential: Alnylam Pharmaceuticals's Earnings Preview ↗

October 29, 2025

Via Benzinga

Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles ↗

October 27, 2025

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event.

Via Benzinga

Peering Into Alnylam Pharmaceuticals Inc's Recent Short Interest ↗

October 21, 2025

Via Benzinga

Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results

October 16, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

$1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today ↗

October 14, 2025

Via Benzinga

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗

October 11, 2025

The Benzinga Stock Whisper Index highlights five stocks seeing increased interest from readers during the week and a look at the potential catalysts driving attention.

Via Benzinga

Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook

October 08, 2025

Carlsbad, CA – October 8, 2025 – Ionis Pharmaceuticals (NASDAQ:IONS) is currently witnessing a remarkable surge in its stock value, nearing a six-year high. This impressive ascent is largely driven by...

Via MarketMinute

ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) Shows Strong Technical Setup for Potential Breakout ↗

October 07, 2025

Alnylam Pharmaceuticals (ALNY) presents a strong technical breakout setup with a high rating for both trend momentum and consolidation quality.

Via Chartmill

27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know ↗

October 06, 2025

Via Benzinga

Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran

October 01, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Healthcare Sector Navigates Turbulent Waters as Drug Pricing Agreements Reshape Market Landscape

September 30, 2025

September 30, 2025 – The healthcare sector today finds itself at a pivotal juncture, experiencing a complex mix of optimism and apprehension. While a landmark drug-pricing agreement between...

Via MarketMinute

Topics Artificial Intelligence Economy Government

New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran

September 29, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

$1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth This Much Today ↗

September 26, 2025

Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 5 years by 10.45% on an annualized basis producing an average annual return of 25.22%. Currently, Alnylam...

Via Benzinga

Pharma Tariffs Back In Spotlight On New Trump Threat ↗

September 26, 2025

President Donald Trump threatened 100% tariffs on some drug imports.

Via Investor's Business Daily

Topics ETFs Government World Trade

Intellia Highlights Clinical Improvements With One-Time Dose Of Experimental Drug ↗

September 25, 2025

Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary...

Via Benzinga

Beyond The Numbers: 28 Analysts Discuss Alnylam Pharmaceuticals Stock ↗

September 19, 2025

Via Benzinga

Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes

September 09, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes

September 08, 2025

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Here's How Much $1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth Today ↗

September 08, 2025

Via Benzinga

$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗

September 02, 2025

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

21 22 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.